Display options
Cite
Yuan C, Morales-Oyarvide V, Khalaf N, et al. Prediagnostic Inflammation and Pancreatic Cancer Survival. J Natl Cancer Inst. 2021;113(9):1186-1193doi: 10.1093/jnci/djab040.
Yuan, C., Morales-Oyarvide, V., Khalaf, N., Perez, K., Tabung, F. K., Ho, G. Y. F., Kooperberg, C., Shadyab, A. H., Qi, L., Kraft, P., Sesso, H. D., Giovannucci, E. L., Manson, J. E., Stampfer, M. J., Ng, K., Fuchs, C. S., Wolpin, B. M., & Babic, A. (2021). Prediagnostic Inflammation and Pancreatic Cancer Survival. Journal of the National Cancer Institute, 113(9), 1186-1193. https://doi.org/10.1093/jnci/djab040
Yuan, Chen, et al. "Prediagnostic Inflammation and Pancreatic Cancer Survival." Journal of the National Cancer Institute vol. 113,9 (2021): 1186-1193. doi: https://doi.org/10.1093/jnci/djab040
Yuan C, Morales-Oyarvide V, Khalaf N, Perez K, Tabung FK, Ho GYF, Kooperberg C, Shadyab AH, Qi L, Kraft P, Sesso HD, Giovannucci EL, Manson JE, Stampfer MJ, Ng K, Fuchs CS, Wolpin BM, Babic A. Prediagnostic Inflammation and Pancreatic Cancer Survival. J Natl Cancer Inst. 2021 Sep 04;113(9):1186-1193. doi: 10.1093/jnci/djab040. PMID: 33739411; PMCID: PMC8522350.
Copy Download .nbib Format: NLM
Share it on

J Natl Cancer Inst. 2021 Sep 04;113(9):1186-1193. doi: 10.1093/jnci/djab040.

Prediagnostic Inflammation and Pancreatic Cancer Survival.

Journal of the National Cancer Institute

Chen Yuan, Vicente Morales-Oyarvide, Natalia Khalaf, Kimberly Perez, Fred K Tabung, Gloria Y F Ho, Charles Kooperberg, Aladdin H Shadyab, Lihong Qi, Peter Kraft, Howard D Sesso, Edward L Giovannucci, JoAnn E Manson, Meir J Stampfer, Kimmie Ng, Charles S Fuchs, Brian M Wolpin, Ana Babic

Affiliations

  1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  2. Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA.
  3. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
  4. The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA.
  5. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  6. Department of Occupational Medicine, Epidemiology and Prevention, Feinstein Institute for Medical Research, Northwell Health, Great Neck, NY, USA.
  7. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  8. Division of Epidemiology, Department of Family Medicine and Public Health, University of California San Diego School of Medicine, La Jolla, CA, USA.
  9. Division of Biostatistics, Department of Public Health Sciences, University of California Davis School of Medicine, Davis, CA, USA.
  10. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  11. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  12. Division of Preventive Medicine and Division of Aging, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  13. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  14. Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT, USA.

PMID: 33739411 PMCID: PMC8522350 DOI: 10.1093/jnci/djab040

Abstract

BACKGROUND: Chronic inflammation may promote initiation and progression of pancreatic cancer, but no studies have examined the association between inflammation in the period before diagnosis and pancreatic cancer survival.

METHODS: We prospectively examined the association of prediagnostic plasma levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 with survival among 492 participants from 5 large US prospective cohort studies who developed pancreatic cancer. Using an empirical dietary inflammatory pattern (EDIP) score, we evaluated whether long-term proinflammatory diets were associated with survival among 1153 patients from 2 of the 5 cohorts. Cox proportional hazards regression was used to estimate hazard ratios for death with adjustment for potential confounders. All statistical tests were 2-sided.

RESULTS: Higher prediagnostic levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 were individually associated with reduced survival (Ptrend = .03, .01, and .04, respectively). Compared with patients with a combined inflammatory biomarker score of 0 (all 3 marker levels below medians), those with a score of 3 (all 3 marker levels above medians) had a hazard ratio for death of 1.57 (95% confidence interval = 1.16 to 2.12; Ptrend = .003), corresponding to median overall survival times of 8 vs 5 months. Patients consuming the most proinflammatory diets (EDIP quartile 4) in the prediagnostic period had a hazard ratio for death of 1.34 (95% confidence interval = 1.13 to 1.59; Ptrend = .01), compared with those consuming the least proinflammatory diets (EDIP quartile 1).

CONCLUSION: Prediagnostic levels of inflammatory biomarkers and long-term proinflammatory diets were inversely associated with pancreatic cancer survival.

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

References

  1. Medicine (Baltimore). 2016 May;95(18):e3582 - PubMed
  2. J Nutr. 2016 Aug;146(8):1560-70 - PubMed
  3. Cancer. 2004 Dec 15;101(12):2727-36 - PubMed
  4. Cancer. 1995 Apr 15;75(8):2077-82 - PubMed
  5. Anticancer Res. 2008 Jan-Feb;28(1B):543-9 - PubMed
  6. Cancer Cell. 2007 Mar;11(3):291-302 - PubMed
  7. CA Cancer J Clin. 2021 Jan;71(1):7-33 - PubMed
  8. JAMA. 2005 Jul 6;294(1):47-55 - PubMed
  9. JAMA. 2001 Sep 26;286(12):1494-7 - PubMed
  10. Br J Cancer. 2014 Jan 7;110(1):183-8 - PubMed
  11. Ann Surg Oncol. 2017 Feb;24(2):561-568 - PubMed
  12. Oncol Rep. 2009 Apr;21(4):1091-5 - PubMed
  13. Eur J Surg Oncol. 2009 Jun;35(6):605-10 - PubMed
  14. Clin Transl Gastroenterol. 2018 Apr 25;9(4):145 - PubMed
  15. J Chronic Dis. 1982;35(6):437-43 - PubMed
  16. JOP. 2012 Mar 10;13(2):199-204 - PubMed
  17. World J Surg. 2016 Sep;40(9):2254-60 - PubMed
  18. Eur J Cancer. 2010 May;46(7):1223-31 - PubMed
  19. Clin Chem. 2002 Oct;48(10):1781-4 - PubMed
  20. Pancreas. 2012 Oct;41(7):1001-7 - PubMed
  21. J Clin Oncol. 2015 Jan 1;33(1):29-35 - PubMed
  22. Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21 - PubMed
  23. Biochem Biophys Res Commun. 2009 May 8;382(3):561-5 - PubMed
  24. J Clin Lab Anal. 2010;24(4):256-61 - PubMed
  25. Lancet. 1991 Aug 24;338(8765):464-8 - PubMed
  26. J Clin Oncol. 2017 Jun 1;35(16):1822-1828 - PubMed
  27. Pancreatology. 2006;6(5):450-3 - PubMed
  28. Am J Epidemiol. 1994 Dec 1;140(11):1016-9 - PubMed
  29. World J Surg. 2011 Apr;35(4):868-72 - PubMed
  30. Scand J Gastroenterol. 2007 Jun;42(6):754-9 - PubMed
  31. Cancer Immunol Immunother. 2006 Jun;55(6):684-98 - PubMed
  32. J Nutr. 2017 Aug;147(8):1567-1577 - PubMed
  33. Immunity. 2005 Nov;23(5):491-502 - PubMed
  34. Gastroenterology. 2014 Feb;146(2):357-373 - PubMed
  35. Cancer Cell. 2011 Jun 14;19(6):728-39 - PubMed
  36. Gut. 2002 Apr;50(4):535-41 - PubMed
  37. N Engl J Med. 1989 Jul 20;321(3):129-35 - PubMed
  38. J Immunol. 2004 Sep 15;173(6):3844-54 - PubMed
  39. J Clin Oncol. 2013 Nov 20;31(33):4229-34 - PubMed
  40. J Womens Health. 1997 Feb;6(1):49-62 - PubMed
  41. Br J Cancer. 2005 Jan 17;92(1):21-3 - PubMed
  42. Nat Rev Cancer. 2011 Nov 24;11(12):886-95 - PubMed
  43. Mutat Res. 2008 Jul-Aug;659(1-2):15-30 - PubMed
  44. Oncology. 2000 Nov;59(4):296-301 - PubMed
  45. Crit Rev Oncol Hematol. 2016 Dec;108:146-153 - PubMed

Publication Types

Grant support